Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) Enterprise Value (2017 - 2025)

Dianthus Therapeutics has reported Enterprise Value over the past 8 years, most recently at -$346.6 million for Q3 2025.

  • Quarterly results put Enterprise Value at -$346.6 million for Q3 2025, down 23.3% from a year ago — trailing twelve months through Jun 2025 was -$256.1 million (up 29.0% YoY), and the annual figure for FY2024 was -$274.4 million, down 57.95%.
  • Enterprise Value for Q3 2025 was -$346.6 million at Dianthus Therapeutics, down from -$256.1 million in the prior quarter.
  • Over the last five years, Enterprise Value for DNTH hit a ceiling of -$52.9 million in Q1 2023 and a floor of -$377.0 million in Q1 2024.
  • Median Enterprise Value over the past 4 years was -$189.9 million (2023), compared with a mean of -$201.6 million.
  • Biggest five-year swings in Enterprise Value: soared 60.38% in 2023 and later crashed 612.8% in 2024.
  • Dianthus Therapeutics' Enterprise Value stood at -$75.5 million in 2022, then tumbled by 130.12% to -$173.7 million in 2023, then tumbled by 57.95% to -$274.4 million in 2024, then decreased by 26.32% to -$346.6 million in 2025.
  • The last three reported values for Enterprise Value were -$346.6 million (Q3 2025), -$256.1 million (Q2 2025), and -$263.2 million (Q1 2025) per Business Quant data.